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Abstract
The objective of this review is to focus on putative modified epithelial functions related to allergy. The
dysregulation of the epithelial barrier might result in the allergen uptake, which could be the primary defect in the
pathogenesis of allergic reaction. We review the literature of the role of respiratory epithelium as an active barrier,
how allergens are transported through it and how it senses the hostile environmental allergens and other
dangerous stimuli.
Introduction
Acute allergic reactions are known to be symptomatic
type-I hypersensitivity responses caused by an allergen
cross-linking specifically with anti-IgE molecules on the
surface of pre-sensitized mast cells [1-4]. In Europe the
incidence of allergies rapidly increasing and thus we are
facing an epidemic outburst of these diseases [5]. Even
though costs per a patient are usually small allergies
cause a major economical burden to the society, since
up to 20% of the population now suffers from these dis-
orders for instance in Finland [6]. Because of this the
Finnish authorities have launched an “Allergy project
2008-2018”, where a new direction has been taken. Here
the patients will now be tolerated towards the antigens
instead of avoiding them [6].
Currently there are two, partially different basic the-
ories on the pathogenesis of allergy. For decades the pri-
mary assumption has been that allergy is caused by
unbalanced and overactive immunological responses
against allergens, mostly driven by activated Th2 cells
and due to aberrant T- regulatory cells. The second
more recent hypothesis relies on the dysregulation of
the epithelial barrier, which might result in the allergen
uptake as a primary defect in the pathogenesis of aller-
gic reactions. There is a wealth of literature on T cell
responses in allergic diseases [7,8], and thus the objec-
tive of this review is to focus on putative modified
epithelial functions related to allergy [9-11].
Epithelium as an active barrier
Respiratory epithelium is the first barrier to the external
environment and thus crucially important in the protec-
tion of the internal environment. Normally three inde-
pendent and complex networks connect epithelial cells
to each other; desmosomes, adherens junctions, and
tight junctions [12]. The respiratory epithelium senses
changes in its local environment such as the allergen
exposure and also actively responds to these changes
[13,14].
Interleukin (IL)-25, IL-33, and thymic stromal lym-
phopoietin (TSLP) are cytokines, which have a role in
Th2-type allergic responses [15]. Previously the epithe-
lium was considered only as a barrier, but now it is con-
sidered as a central player in controlling the immune
function release of innate cytokines-promoting Th2
responses and the activation of local dendritic cells
[16-18]. The exposure of airways to aeroallergens
induces a rapid release of these three cytokines from the
epithelial cells into the airway lumen and initiates an
allergic immune response [19,20].
Recently, disruption in the epithelial barrier has been
included into the primary defects in allergic diseases.
Atopic dermatitis (i.e. atopic eczema) is an allergic dis-
ease characterized by the defective epidermal barrier
function, immunological dysregulation, and IgE-
mediated sensitization to pollen allergens and food
[21,22]. Loss-of-function mutations in the filaggrin gene
are linked to atopic dermatitis and other related diseases
including peanut allergy [22]. Filaggrin dysfunction has
been suspected to cause the impaired barrier function in
the skin allowing the allergen penetration and followed
by a local inflammation. To more directly verify the link
between mutated filaggrin and the barrier dysfunction
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an elegant survey with wasp allergies was conducted.
Wasp stings bypass the skin surface and antigen is
injected deep into the dermis [21]. Patients with atopic
dermatitis have an increased frequency of the most
common filaggrin null mutations (R501X and 2282del4)
compared to those with wasp allergy and healthy sub-
jects. This data supports the role of mutated filaggrin in
the epithelial dysfunction resulting in the allergic sensiti-
zation [21].
The respiratory epithelium is constantly facing hostile
injurious stimuli causing damage. Proliferation and dif-
ferentiation of resident progenitor and stem cells repair
the damages and try to maintain the protective barrier
[23]. The concept of unified airways suggests that in
addition to the anatomic continuity, also inflammation
influences the homeostasis of other parts of the airway
[24-26]. In vivo challenge with the birch pollen allergen,
Bet v 1, leads to instant leukocyte extravasation into
conjunctival and nasal mucosa only in patients allergic
to birch pollen, but not in healthy subjects.
Allergen transport through the epithelium
Several of the known allergens are proteases [27,28].
Impaired epithelial barrier function can be a direct
consequence of proteolytic activity of inhaled allergens,
including house dust mite (HDM) [29]. After causing
injury to the epithelium Der p 1 m, the major allergen
in HDM, can enter the tissue and induce mediate
inflammation via Toll-like receptor 4 (TLR4) [30,31].
Der p 2, another allergen from HDM activates respira-
tory epithelial cells, indicating that this non-proteolytic
allergen, in addition to its immunogenic properties,
can aggravate a respiratory airway disease by an adju-
vant [32].
Also toxic perturbations such as exposure to cigarette
smoke can induce epithelial cell gaps and a decrease in
trans-epithelial resistance [33]. Cigarette smoke expo-
sure induces also a significant increase in the allergen
uptake to epithelium. Thus smoking reduced the barrier
function of the respiratory epithelium for allergens and
contributed to exacerbation of an allergic disease [33].
A new concept is to focus on the aberrant innate
responses of the respiratory epithelium to viral or bac-
terial infections and how these responses may increase
the risk of allergic diseases [34]. As novel sequencing
techniques are emerging the role of the resident respira-
tory microbiome and its influence on the local immune
response can now be studied more efficiently [35,36].
The very rapid increase in the incidence of allergic
diseases over the last 30 years and the differences in the
prevalence of an allergic disease between industrialized
and developing countries both suggest that something
else than variations in human genetics is the cause of
this allergic epidemic [5,6,37]. These observations led to
the generation of the “hygiene hypothesis”, i. e, the lack
of an early microbial stimulation or an exposure to soil
and dirt results in dysregulated immune responses to
allergens later in life [6,38]. The respiratory epithelium
is the home to microbiome, which is estimated to be
composed of 10 × 1012 microbes, with a diversity of
greater than 1,000 species within each individual [39].
The international Human Microbiome Project aims to
define the human microbiome from various locations
within the body both in health and in various diseases
[40,41]. Several different combinations of local microbes
can contribute to the local environment and thus alter
the barrier functions of the respiratory epithelium.
Allergen-containing subpollen particles from timothy
grass were shown to first bind to and then be interna-
lized by primary epithelial cells in a dose dependent
manner. The binding was enhanced with the surfactant
protein -D and coincided with the secretion of Interleu-
kin (IL)-8 [42]. Timothy grass pollen allergen Phl p 1
activated respiratory epithelial cells by a non-protease
mechanism [43]. Enhancement of TGF-beta, IL-6 and
IL-8 induced by Phl p 1 might provide an indirect
mechanism through which the allergen may cross the
epithelial barrier. Furthermore, recent observations also
indicated that timothy grass allergen Phl p 1 is actively
transported though the epithelium [44].
Already one minute in vivo challenge with birch pol-
len caused Bet v 1 binding to conjunctival epithelial sur-
faces in the allergic, but not in the healthy individuals
Figure 1 Bet v 1 binds to and is transported through the
conjunctival epithelium only in allergic, but not in healthy
subjects. Panel a; A conjunctival epithelial biopsy taken from an
allergic patient 1 min after the in vivo birch pollen challenge
indicated a clear Bet v 1 location detected with anti- Bet v 1
antibodies (green staining for Bet v 1). Original magnification × 200.
Panel b; The strong clustered staining of anti-Bet v 1 detected with
gold label particles at the epithelial villus. Bet v 1 was seen to co-
localise with caveolin 2 as shown with double immunoTEM using
an anti- Bet v 1 10 nm gold-labelled antibody and anti-caveolin 2 5
nm gold-labelled antibody, magnification × 27 500. Bet v 1 was
almost solely (75%) co-localised with a caveolar marker protein
caveolin 2.
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(Figure 1a) [45]. Bet v 1 entry into the epithelium was
evident also in immuno transmission electron micro-
scopy (TEM) in the allergic, but not in the healthy indi-
viduals. One minute after the birch pollen perturbation,
before the fulminant clinical symptoms, Bet v 1 was
found both on the cell surfaces of villae as well as within
the villae, in the cytoplasm, in intracellular vesicles, and
also in the nuclei of epithelial cells in allergic patients
[45]. At the same time there was no Bet v 1 in the con-
junctival epithelial cells of the healthy subjects (Cell
level, Table 1). In conjunctival biopsies anti-Bet v 1
staining was seen dispersed into the more basal epithe-
lial cell layers (Tissue level, Table 1). These observations
support a very rapid traffic through the epithelium in
allergic patients, but not in healthy subjects. Currently
the putative receptor(s) mediating this allergen binding
and facilitating its transport through the epithelium is
not known. A striking specificity is observed when birch
pollen allergic subjects were also challenged with
timothy grass pollen and no entry of this pollen allergen
Phl p 1 into epithelial cells was detected (R. Renkonen
unpublished data). While the specific transport mechan-
ism for birch pollen remains unsolved the first hints of
the role of caveolae in this have been obtained. In the
double immunoTEM stainings caveolin 2, but not
caveolin 1 or 3, was present on the conjunctival epithe-
lial surface in the same clusters as Bet v 1 (Figure 1). A
great majority of anti-Bet v 1 staining in the epithelial
cells was colocalized also with another caveolar marker,
flotillin 2. Thus the observed Bet v 1 traffic could
involve an active lipid raft and caveolar-dependent
transport [46].
While the above data suggests a caveolar-dependent
traffic, the primary contact with the epithelium is still
unknown. Small proteins like cholera toxin or much lar-
ger cargo like full Pseudomonas bacteria can be trans-
ported to and through epithelial cells via lipid raft and
caveolar mechanisms [47]. In the gastrointestinal tract
food proteins are the targets for lysosomal degradation
while selective food allergens are protected from this
when they are transported across the intestinal epithe-
lium by their binding to cell surface IgE/CD23 (FcεRII)
complexes. The presence of IgE/CD23 on the intestinal
epithelium provides means for intact transcytosis for
food allergens across the epithelium, and this can lead
to classical mast cell-dependent type I anaphylactic
allergic reactions [48]. So far this direct interaction with
IgE and its low affinity receptor CD23 has been detected
only in the intestinal but not in the respiratory epithe-
lium. However, as the transport of pollen allergens
through the respiratory epithelium seems to be specific,
e.g., our patients allergic to birch pollen do not trans-
port timothy grass allergen and vice versa, it is most
likely antibody-dependent. Some other allergens are
actively and specifically transported through the respira-
tory epithelium. Ovalbumin allergen (OVA) is taken up
rapidly via the respiratory epithelium both in the nose
and lower airways in a rodent model [49]. Also, human
respiratory epithelial cells internalize timothy grass pol-
len allergen, Phl p 1 [44].
Bet v 1 associated epithelial caveolar proteins
Microscopy provided evidence for the novel hypothesis
of active allergen transport. This led us to clarify
whether the Bet v 1-associated epithelial proteins act as
putative receptors in this intraepithelial traffic. With the
help the covalently matrix-bound Bet v 1 antigen and
nasal epithelial protein lysates collected from both
healthy and allergic subjects we began to identify these
interacting proteins. By extensive analyses applying both
database-related and de novo identifications we gener-
ated a shortlist of Bet v 1-binding epithelial proteins
found only in the allergic patients. Six out of these six-
teen proteins (40%) had previously been identified as
caveolar proteins: ACTG, ANXA2, CALM, KCNA5,
PLEC1, STML2 (Table 2, [46]). While the entire human
proteome consists of less than 1% of caveolar proteins,
the Bet v 1 associated list of proteins was highly
enriched with the caveolar proteins. This observation
provided independent support for the observation that
Bet v 1 could be transported actively through the
epithelium within caveolae at the onset of an allergic
reaction.
Bet v 1 associated epithelial caveolar lipids
The primary contact between the allergen and the
epithelium can be mediated by lipids. Bet v 1 has been
shown to bind cholesterol and enter the epithelium of
allergic patients in cholesterol- and glycolipid-rich
caveolae [50-52]. We performed 3-D modeling of Bet v
1 and its possible lipid ligands. We modeled a large
Table 1 Bet v 1 distribution in the epithelial cells and
tissues in allergic patients
Distribution of Bet v 1





Tissue level On the apical surface 7%
Epithelial cell layer 1 29%
Epithelial cell layer 2 26%
Epithelial cell layer 3 22%
Epithelial cell layer 4 16%
Note that the epithelium of healthy patients neither bound nor transported
the Bet v 1 allergen.
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group of putative lipid ligands for Bet v 1 on the atomic
level with a computational ligand docking using the
CDOCKER algorithm, which is based on the CHARMm
force field engine [53].
We conducted 3-D docking with both experimentally
verified Bet v 1 ligands as well as with larger lipid mole-
cules for which experimental affinity studies were not
available. In silico data suggested that Bet v 1 can bind
also to more complex amphiphilic molecules like cera-
mides, sphingomyelins and even glycolipids, all of which
are present on lipid rafts and caveolar surfaces [53].
Thus a binding model was drafted, where the hydropho-
bic tail groups of lipids are located in the central Y-
shaped cavity of the Bet v 1 molecule, while the polar
head group points out from the molecule. Taken
together, these data provide a hypothesis on how Bet v
1 could directly interact with epithelial surface lipids
[53]. It remains to be verified experimentally whether
any of these lipids actually participate in the birch pol-
len uptake on the epithelial surfaces during the early
phases of allergic reactions.
Allergen induced responses on the epithelium
A hypothesis-free approach in order to analyze the dif-
ferences between respiratory epithelial swabs from aller-
gic and healthy subjects during the asymptomatic winter
period [45,46,54], 182 significantly differentially
expressed transcripts (and thus proteins after converting
them to corresponding proteins) in between these two
groups could be detected. Twenty-two epithelial cell
surface receptors displayed enhanced expression levels
in allergic compared to healthy subjects and eight out of
them were found in lipid rafts/caveolae according to
manual PubMed literature search (Table 3, [45]). The
kinetics of the Bet v 1 caveolar traffic resembles in
many ways other previously known caveolar-dependent
phenomena, such as the entry of bacterial toxins, whole
viruses, bacteria or even parasites [55-61].
In another approach the response of epithelium to the
birch pollen challenge was analyzed. Nasal epithelial cell
swabs were collected from both allergic and healthy sub-
jects in winter (no symptoms) and during the birch pol-
len season in May when allergic patients suffer from
clinical symptoms. The allergic subjects displayed 331
transcripts between these two time points [46]. Surpris-
ingly the healthy subjects displayed a much stronger
response, while they remained without any clinical
symptoms through the experiment. Out of the 605 tran-
scripts recorded as altered in healthy controls, the Gene
Ontology (GO) category Immune response was the
most significantly upregulated. This immune response
was not present in allergic subjects giving us the first
Table 2 Bet v 1-associated nasal epithelial proteins found in the allergic, but not in the healthy subjects
Proteins found in caveolae and lipid
rafts.
Name Functions
ACTG, gamma actin A subunit of microfilaments, one of the three major components of the cytoskeleton
ANXA2, Annexin 2 Belongs calcium-binding proteins, suppresses phospholipase A2 and thus inhibits inflammation.
CALM, Calmodulin Belongs calcium-binding proteins, regulation of nuclear transport.
KCNA5 Voltage-dependent potassium ion permeability, has a role in regulating the secretion of insulin
PLEC1, Plectin Intermediate filament binding protein
STML2, Stomatin 2 Colocalized at intercellular junctions and regulated gap junctions and lipid domain organization.
Other epithelial proteins
Name Functions
CROCC, Ciliary rootlet A cytoskeletal-like structure in ciliated cells
DCD, Dermcidin Displays antimicrobial activity thus limiting infection by potential pathogens, such as E.coli and S.
aureus.
ECHB Participates in lipid metabolism.
EPIPL, Epiplakin A cytoskeletal linker protein, interactions between epiplakin and intermediate filaments
GNDS, Ral/RalBP1 Plays a role in endocytosis and vesicle sorting and migration.
K1C18, Cytokeratin 18 A subunit of intermediate filament, one of the three major components of the cytoskeleton
MARCO Scavenger receptor, a major mediator of non-opsonized E. coli phagocytosis clearance of bacteria in
vivo
MYCB2 Mediates ubiquitination and subsequent proteasomal degradation of target proteins
S100P Overexpressed in epithelium in psoriasis, wound healing, skin cancer, inflammation, calcium-binding
TBA8, Alpha-tubulin The major constituent of microtubules, one of the three major components of the cytoskeleton.
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hint to that allergy might be, at least partially, caused by
lack of protective immune defense at the epithelial sur-
faces [46]. These results suggest that to truly learn
about the pathogenesis of diseases one must analyze
also how the healthy subjects respond.
A precise time-series analysis was performed with
allergic patients and healthy control subjects. The first
nasal epithelial specimens were obtained in February
when all subjects were symptom-free and the following
four nasal epithelial cell swabs were collected from each
subject at weekly intervals starting in mid-April when
the birch pollen season in Finland begins. While the
healthy subjects remained totally symptomless through-
out this whole period of time the allergic subjects began
to have symptoms already in April, which worsened
along with the birch pollen season [54].
Patients allergic to birch pollen showed 105 uniquely
regulated nasal epithelial transcripts (converted to pro-
teins for further analyses) with increasing clinical symp-
toms. Dyneins were among the most enriched Gene
Ontology (GO) categories in the list of proteins. Dyneins
are molecular motors for the epithelial intracellular
caveolar cargo traffic along the microtubuli and ciliary
movements [54].
The epithelial cells collected from healthy subjects dis-
played 22 unique and significantly altered transcripts
during the birch pollen season when compared to the
winter season. Forty percent of these uniquely regulated
genes, i.e., CXCL6, CXCL9, CXCR2, CXL10, FPR1, IL1
and IL8, NKG7, and PGSG belonged to the Gene Ontol-
ogy category Immune response (GO:0006955). This
Immune response category contains altogether only few
percent of all annotated proteins of the human
proteome (amigo.geneontology.org). Thus the birch pol-
len allergen induced a strong epithelial immune
response in healthy subjects, while this response was
lacking from the epithelium of allergic patients [54]. It
is remarkable that a similar immunoresponse has been
documented on primary human nasal epithelial cells iso-
lated form healthy subjects after HMD challenge and
that this response is lacking from the epithelium of
allergic subjects. Here also the number of modified tran-
scripts was significantly larger in healthy epithelium that
in the allergic (555 compared to 301 probe sets). Many
transcripts remain unaffected by the HDM-exposure in
the allergic epithelium while these same transcripts were
modified by HDM in the healthy epithelium. Genes
involved in immunoresponse and with this expression
pattern are: IL-1b, IL-8, CXCL2, CXCL3, CCL20, CTGF,
HBEGF, and AREG [14,62,63].
How does the epithelium detect danger and respond to
it? There are extensive recent reviews on the topic [14,64].
In short the respiratory epithelium continuously senses
the changes in its environment. There are several families
of receptors to carry out this including eleven human
Toll-like receptors (TLR1- 11). They are all membrane
bound receptors which mediate effects through dimeriza-
tion and complex downstream signaling [65]. Other recep-
tors involved in the initiation of epithelial innate immunity
include the families protease-activated receptors (PAR1-4),
NOD and leucine-rich repeats containing receptors
(NLRs) including NOD1 and NOD2 [14,64]. Although a
great number of research data has been published on this
field with a special reference to the anti microbial defense
the true role of this arm on immunology in the develop-
ment of allergies and asthma remains to be solved [66,67].
Table 3 Membrane-bound receptors associated with lipid raft and/or caveolae and displaying upregulated transcript
expression levels in allergic compared to healthy conjunctival specimens
ARBK1,
Beta-adrenergic receptor kinase 1




Potent inhibitor of the complement membrane attack complex (MAC) action. Involved in signal
transduction for T-cell activation complexed to a protein tyrosine kinase.
EFNB3,
Ephrin-B3
May play a pivotal role in forebrain function. Binds to, and induces the collapse of, commissural
axons/growth cones in vitro.
EPHA1,
Ephrin type-A receptor 1
Receptor for members of the ephrin-A family. Binds with a low affinity to ephrin-A1
P2RY4,
P2Y purinoceptor 4
Receptor for UTP and UDP coupled to G-proteins that activate a phosphatidylinositol-calcium second
messenger system.
SSR4,
Somatostatin receptor type 4
The activity of this receptor is mediated by G proteins, which inhibit adenylyl cyclase.
TNFL8,
Tumor necrosis factor ligand superfamily
member 8
Cytokine that binds to TNFRSF8/CD30. Induces proliferation of T-cells.
TRPA1,
Transient receptor potential cation channel
subfamily A member 1
Has a central role in the pain response to endogenous inflammatory mediators and to a diverse
array of volatile irritants, such as mustard oil, garlic and capsaicin.
A short characterization from SwissProt is included.
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Conclusions
Could allergy be either a epithelial disease or a disease
of the immune system? So far it seems that both
answers are correct. There is a wealth of immunologi-
cal studies indicating an altered regulation of IgE pro-
duction, Th2-response, and other hyperimmune
responses, which we do not discuss further in this
Review. The role of the epithelial barrier function in
allergies has recently also been identified. Filaggrin
mutations have been identified constantly in atopic
dermatitis and this provoked increasing interest in stu-
dies trying to identify the epithelial barrier dysfunction
in allergic diseases [68,69]. It is also interesting that
mutations in the filaggrin gene not only cause atopic
dermatitis, but also lead to a significantly increased
risk for other allergic diseases and asthma in the con-
text of eczema [70]. The defective airway epithelial
barrier functions together with disrupted tight junc-
tions and innate immunity are also encountered in
asthma patients. This could explain the significant
impact of viruses and bacteria in acute asthma exacer-
bations [71,72]. The expensive genome-wide associa-
tion (GWA) studies have yielded several hypothesis-
free candidate genes with known or suspected links to
epithelial barrier functions for further analyses in aller-
gic diseases [73,74]. Finally novel approaches pursuing
to measure epithelial proteomics [75] and lipidomics
[76] will become possible in near future thus allowing
us to broaden the DNA and mRNA based GWA
analyses.
Taken together, new data has been generated on the
role of modified epithelial barrier functions in the early
phases of allergic diseases. Active transport of allergens
through the epithelium might be incorporated to the
pathogenesis of allergy. It is possible that the healthy
epithelium displays a strong immune response against
pollen allergens and thus escapes from becoming aller-
gic. This challenges the concept of hypersensitivity as
the only driving force behind allergic reactions. In fact,
if allergy turns out to be, at least in part, a result of
epithelial hyposensitivity, it could have major conse-
quences in the strategies of prevention and treatment of
these diseases. Towards this end, a national allergy pro-
gram was launched in Finland in 2008, which changes
the basic idea of trying to avoid allergens to the concept
of natural exposure and tolerance [6].
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